All News

In what is being called the largest clinical trial to examine the efficacy of poly(ADP-ribose) polymerases (PARP) inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced forms of both prostate and pancreatic cancer.

More intense surveillance and treatment in the first 2 years after a bladder cancer diagnosis could reduce the number of patients whose cancer recurs and lower the death rate from this disease, according to researchers from UCLA’s Jonsson Comprehensive Cancer Center.

Hitting all the highlights of an event as large as the AUA annual meeting is nearly impossible. But since returning home from San Diego, three topics have stuck with me as especially relevant.

Men using long-term, high-dose prescription opioids for back pain were about 50% more likely to be using medications for erectile dysfunction than men with back pain who were not using opioids, researchers reported.

Intensity-modulated radiation therapy may not be more effective than conformal radiation therapy in patients who have undergone radical prostatectomy, say researchers from the University of North Carolina, Chapel Hill.

Surveillance for cancer recurrence, rather than additional chemotherapy or radiation therapy, is sufficient for the vast majority of men who have undergone successful surgery for stage I seminoma, a long-term study suggests.

The effect of percutaneous tibial nerve stimulation in patients with overactive bladder appears to be durable at up to 3 years, a recently published study demonstrates.

The clinical advantages of adjuvant or salvage radiation therapy in patients treated for prostate cancer by radical prostatectomy is currently a much-debated issue and is frequently decided for the individual patient. New evidence, however, seems to indicate that secondary radiation therapy (RT) does not negatively affect urinary continence.

A new study has confirmed that a genetic test that measures cell cycle progression (CCP) can be a useful tool for predicting which patients will have prostate cancer recurrence, especially when combined with existing information from laboratory and pathology tests.

The FDA has approved radium Ra 223 dichloride (Xofigo) injection for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.

Older prostate cancer patients with three or more underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by UCLA urologists.

The push to reform Medicare’s sustainable growth rate (SGR) formula continues in Washington, with support for SGR repeal coming from leading House of Representatives committees.

Saying it’s time to take the guesswork out of buying a legitimate drug online and combat counterfeiters, Pfizer has launched a prescription-fulfillment website for the phosphodiesterase type-5 inhibitor sildenafil citrate (Viagra).

The AUA and the American Society for Radiation Oncology (ASTRO) have released a joint guideline on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence.

A new genomic test for prostate cancer appears to help predict whether men are more likely to harbor an aggressive form of the disease, report researchers from the University of California, San Francisco.

Urologists’ compensation for on call coverage compares favorably with that of some other specialties and exceeds family physicians’ compensation, according to a survey that shows a wide variation in on call compensation by specialty.